bmiMD vs He & She MD
Same $99 opener, opposite amounts of disclosure about what happens next.
bmiMD
Editorial
$99/mo
Compounded semaglutide and compounded tirzepatide, both sold as microdose lines and both priced flat across doses. The $99 semaglutide rate is the twelve-month tier; a single month is $129. Each product page strikes a higher figure through and labels it a limited time offer, without dating it.
Pick it for: Buyers who want the rate pinned before the dose moves
He & She MD
Editorial
$99/mo
Terms paid up front rather than a rolling monthly charge: injectable semaglutide advertises $99 a month against a struck $199 and bills $1,188 for the year, while injectable tirzepatide bills $1,908. The oral line is $199 a month for six months and then renews at $1,434 per six months, a figure carried in a footnote rather than on the card.
Pick it for: Buyers weighing a third priced line alongside the injection
Our verdict
BMIMD states a flat rate; He and She MD publishes no dose behavior. The figures match, so the disclosure is the whole difference.
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.